0
0
Most people who fight high cholesterol fight it every single day.
A pill in the morning. Maybe another one at night. Refills every month. Blood tests every few months to see if the numbers held. It never really ends, because the medicine only works while you keep taking it.
Now a small group of patients has tried something very different. They got one infusion. Just one. And a full year later, their “bad” cholesterol was still about half of what it had been.
The treatment is a CRISPR cholesterol therapy called CTX310. The one-year results were published in the New England Journal of Medicine and presented at the European Society of Cardiology’s 2026 meeting at the end of August. Here is what it actually did, what it did not prove, and why the idea behind it is much older than CRISPR.
What the CRISPR Cholesterol Trial Found
The trial was run by doctors at Cleveland Clinic. It was a Phase 1 study, which means it was the very first time this treatment was given to people. The main job of a Phase 1 trial is to check safety, not to prove that something works.
Here are the plain facts:
- 15 people took part.
- All of them had cholesterol or triglyceride problems that medicine was not controlling well enough.
- Each person got one infusion, at one of several dose levels.
- At the highest dose, LDL (“bad”) cholesterol was 52.5% lower after 12 months.
- Triglycerides, another blood fat linked to heart disease, were 47.8% lower.
- The researchers reported no serious side effects linked to the treatment during that year.
“It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment,” said Dr. Luke Laffin, the cardiologist who was the study’s first author, in Cleveland Clinic’s announcement.
How One Dose Can Last a Year
A daily pill works only while it is in your body. Stop taking it, and before long your body goes back to its old habits. So you take it again. And again.
CTX310 tries something else. It goes after the instruction behind the problem.
Inside your liver there is a gene called ANGPTL3. Think of a gene as a small instruction in your body’s recipe book. This one tells the liver to make a protein that slows down how fast your body clears fat out of the blood. More of that protein, more fat hanging around in your blood.
CRISPR is a tool that can find one exact spot in your DNA and cut it. CTX310 carries that tool to the liver and switches the ANGPTL3 instruction off. In the people who got the highest dose, levels of the protein dropped by nearly 80%, according to reporting in TIME.
A pill has to be taken again tomorrow because tomorrow the liver is still following the old instruction. After the edit, the instruction itself has changed. That is why one dose can keep working.
The Part Most Headlines Skipped: Nature Ran This Experiment First
Here is the part that surprised me most.
Scientists did not pick ANGPTL3 at random. They picked it because some people are born with this gene already switched off.
Years ago, researchers studying families with unusually low blood fats traced it to broken copies of ANGPTL3. The condition even has a name: familial combined hypolipidemia. People with it have very low cholesterol and triglycerides, and studies of them found they appear to be protected from heart disease rather than harmed.
In 2017, two studies looked at this closely. A large genetic study in the New England Journal of Medicine found that people carrying a broken copy of the gene had lower blood fats and lower odds of heart disease. The other, in the Journal of the American College of Cardiology, found that carriers had about 12% lower LDL cholesterol and 17% lower triglycerides than non-carriers, and that the handful of people with no working copy at all showed no sign of plaque in their heart arteries.
So CTX310 is not really inventing something new. It is copying something some human bodies already do, apparently without trouble. That is a big reason doctors are hopeful it will be safe over the long run.
Hopeful is not the same as proven, though. Which brings us to the honest part.
What This Trial Does Not Tell Us Yet
It would be easy to read “one shot, cholesterol cut in half” and think the problem is solved. It is not. Not yet. Here is what is still unknown:
- It was only 15 people. Small trials can miss rare side effects that only show up when thousands of people are treated.
- They were not typical patients. Everyone in the trial had hard-to-treat lipid disorders. Nobody has tested this on people with ordinary high cholesterol yet.
- One year is not a lifetime. The company’s chief executive, Samarth Kulkarni, told TIME the effect may last “presumably for life, but at least for one year.” The honest word there is presumably.
- A DNA edit is meant to stay. That is the whole point, and it is also why regulators ask for long follow-up. The patients in this trial will be watched for 15 years.
- It did not measure heart attacks. Lower cholesterol usually means fewer heart attacks, but this trial was not big or long enough to show that directly.
- The company paid for the study. The trial was funded by CRISPR Therapeutics, which makes CTX310. That is normal for early drug trials, but it is worth knowing.
The company says bigger studies have already started. Until they finish, this is a promising first step, not a treatment you can ask for.
And one thing that matters right now: if you take cholesterol medicine, keep taking it. Nothing in this study is a reason to stop. Stopping a medicine can quietly undo the protection it was giving you, as we saw when researchers followed people who stopped taking Ozempic.
Why the Idea Feels So Hopeful
Why does this story grab people, even people who have never had a cholesterol test?
I think it is because almost everyone knows what it feels like to manage a problem that never gets fixed. The daily pill. The same argument that comes back every few weeks. The habit you promise to quit every Monday. We get very good at handling the symptoms, and very tired of handling them.
Sometimes the daily fix is exactly right, and there is no shame in it. Medicine you take every day is still a gift. But most of us also carry a quiet wish that something could be fixed at the source. Not managed. Changed.
That wish is very old. Long before anyone knew what a gene was, people were already saying that repeating the same remedy day after day could only keep a problem at bay, and that real healing would have to come from somewhere deeper, once, and for good. The ancient writers even had a phrase for it: not a better routine, but a new heart. They believed that kind of change was not something a person could do to themselves, but something God could do for them.
A liver cell following a new instruction is not the same thing as a changed life, of course. But it is a striking picture of it.
What You Can Do Today
You do not need a new treatment to take care of your heart this week. A few simple things help almost everyone, and none of them cost money:
- Keep taking any medicine you have been prescribed, even if you feel fine.
- Walk. A brisk walk most days is one of the best-studied things you can do for your heart.
- Know your numbers if you can. If you have a chance to get a cholesterol check at a clinic or health event, take it. High cholesterol usually causes no symptoms at all.
- Be careful with “one-time cure” ads. This therapy is not for sale anywhere. Anyone selling a “gene fix” for cholesterol today is selling something else.
If you are curious what early warning can and cannot do for your heart, you might also like our piece on a blood test that can flag heart disease 15 years early. And if you take several medicines already, it is worth knowing about the prescribing cascade, where a side effect ends up treated like a new illness.
Questions People Ask About the CRISPR Cholesterol Treatment
What is CTX310?
CTX310 is an experimental CRISPR gene-editing therapy made by CRISPR Therapeutics. It is given as a single infusion and travels to the liver, where it switches off a gene called ANGPTL3. Turning off that gene lowers LDL cholesterol and triglycerides in the blood. As of 2026 it is only available inside clinical trials.
How much did the CRISPR cholesterol treatment lower cholesterol?
In a 15-person Phase 1 trial led by Cleveland Clinic, people who received the highest dose of CTX310 had 52.5% lower LDL cholesterol and 47.8% lower triglycerides one year after a single infusion. The results were published in the New England Journal of Medicine in August 2026.
Is the CRISPR cholesterol gene edit permanent?
The edit changes DNA in liver cells and is designed to last, and effects in the CTX310 trial were still present after one year. Whether it lasts for life is not yet known. Patients in the trial are being followed for 15 years, which is the long-term safety monitoring recommended for gene-editing therapies.
Is it safe to switch off the ANGPTL3 gene?
Some people are born with ANGPTL3 already switched off, a condition called familial combined hypolipidemia. Studies of these people have found very low blood fats and apparent protection from heart disease, and no serious illness has been clearly tied to the missing gene. That is encouraging, but the long-term safety of switching the gene off with CRISPR still has to be confirmed in larger and longer studies.
Should I stop taking statins because of the CRISPR cholesterol trial?
No. The CRISPR cholesterol treatment CTX310 is experimental, has only been tested in 15 people with hard-to-treat lipid disorders, and is not available outside clinical trials. Anyone taking cholesterol medicine should keep taking it as prescribed and talk to a health worker before making any change.
Let’s Talk About It
If a one-time treatment like this becomes available someday, would you choose it over a daily pill, even knowing the change is meant to be permanent? Why or why not? Tell us in the comments. We read every one.
Share This
Short version: One infusion. A full year later, “bad” cholesterol was still about half of what it was. Only 15 people so far, so it is early, but the science behind it is fascinating. https://bgodinspired.com/?p=117368
Longer version: I did not know some people are born with a gene switched off that keeps their cholesterol very low, and their hearts seem better for it. Scientists just copied that with a one-time CRISPR edit. Early days, but worth a read: https://bgodinspired.com/?p=117368
For the family group chat: Interesting new heart research. Not a reason to stop your meds! But a hopeful look at where medicine might be going: https://bgodinspired.com/?p=117368
